Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 -- Completion of 1-year open-l...

Related Keywords

United States ,American ,Bruce Mackle ,Larry Ereshefsky ,International Societies For Investigative Dermatology ,Reviva Pharmaceuticals Holdings Inc ,Clinical Program ,Drug Administration ,Securities Exchange ,Research Archives ,American Thoracic Society ,Nasdaq ,Pharmd Follow The Molecule ,International Conference ,Lifesci Advisors ,Company Phase ,Exchange Commission ,American Society For Pharmacology ,Pharmaceuticals Holdings ,International Societies ,Investigative Dermatology ,Laxminarayan Bhat ,Recent Business ,Russell Microcap ,Thoracic Society ,Medical Research Archives ,American Society ,Experimental Therapeutics ,Annual Scientific Convention ,Biological Psychiatry ,State Healthcare Agencies ,Six Months Fiscal Year ,Negative Syndrome Scale ,Clinical Global Impression ,Orphan Drug Designation ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Relations Contact ,Sci Advisors ,Six Months Ended June ,Months Ended June ,